BioForest

Found 21,706 articles

• 

  BioSpace Launches 2022 Hotbed Maps to Highlight Thriving Life Sciences Clusters

  1/18/2022

  As BioSpace proudly introduces our 2022 Hotbed Maps, let’s explore the industry’s most thriving territories, research leading employers and search for relevant jobs on BioSpace.

• Athira Pharma to Participate in Upcoming May 2023 Investor Conferences

  5/8/2023

  Athira Pharma, Inc., a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, announced that it will participate in the following upcoming investor conferences.

• MCRA Assists Noctrix Health with FDA Marketing Authorization via the De Novo Pathway for the NTX100 Tonic Motor Activation System

  5/8/2023

  MCRA, LLC is pleased to announce its role in assisting Noctrix Health obtain marketing authorization via a De Novo Request from the U.S. Food and Drug Administration (FDA) for the NTX100 Tonic Motor Activation (NTX100 TOMAC) System.

• Sana Biotechnology Announces Preclinical Data Published in Nature Biotechnology Demonstrating its Hypoimmune-Engineered Cells Escape Immune Detection and Survive While Remaining Fully Functional

  5/8/2023

  Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that Nature Biotechnology has published a paper titled “Hypoimmune induced pluripotent stem cells survive long term in fully immunocompetent, allogeneic rhesus macaques.”

• Know Labs, Inc. to Host Review of Second Quarter Fiscal Year 2023 Results on May 15, 2023

  5/8/2023

  Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced it will host a webcast to review business updates and results for its second quarter of the fiscal year 2023 ended on March 31, 2023, on May 15, 2023, beginning at 1:30 pm PT.

• Sana Biotechnology Reports First Quarter 2023 Financial Results and Business Updates

  5/8/2023

  Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today reported financial results and business highlights for the first quarter 2023.

• Chinook Therapeutics Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - May 5, 2023

  5/5/2023

  Chinook Therapeutics, Inc. today announced that the Compensation Committee of the Company’s Board of Directors approved new employment inducement grants of stock options to purchase a total of 88,000 shares of common stock and restricted stock units for 44,600 shares with a grant date of April 28, 2023.

• Impel Pharmaceuticals to Report First Quarter 2023 Financial Results on Friday, May 12, 2023

  5/5/2023

  Impel Pharmaceuticals Inc. announced it will host a live webcast on Friday, May 12, 2023, at 8:30 a.m. ET to report its first quarter 2023 financial results and provide a business update.

• Arbele celebrates its 7th anniversary as a clinical-stage immunotherapy biotech and the opening of TibTech, its cancer diagnostics subsidiary

  5/5/2023

  Arbele, a biotechnology company dedicated to fighting gastrointestinal cancers, celebrates its 7th anniversary and the opening of Tiberias Technology, its accredited lab for cancer screening and in vitro diagnostics, at the Hong Kong Science and Technology Park.

• CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 05, 2023

  5/5/2023

  CTI BioPharma Corp. announced that an authorized subcommittee of the Compensation Committee of its Board of Directors granted an equity award to a new employee as an equity inducement award outside of the Company's Amended and Restated 2017 Equity Incentive Plan and material to the employee's acceptance of employment with the company.

• Chinook Therapeutics Announces Upcoming Presentations and Investor Conference Call at the 60th European Renal Association (ERA) Congress

  5/5/2023

  Chinook Therapeutics, Inc. today announced upcoming data presentations at the 60th ERA Congress from June 15 – 18, 2023, both virtual and live in Milan, Italy.

• Visus Therapeutics Presents Topline Clinical Data from Phase 3 Pivotal BRIO-I Trial of BRIMOCHOL™ PF for the Treatment of Presbyopia at Eyecelerator @ ASCRS 2023

  5/4/2023

  Visus Therapeutics Inc., a clinical-stage biopharmaceutical company focused on developing multi-targeted ophthalmic therapies for indications in the front and back of the eye, today presented key topline data from the pivotal Phase 3 BRIO-I clinical trial.

• Sonoma Bio Co-Founder and Chief Executive Officer Jeffrey Bluestone, Ph.D., Elected to the National Academy of Sciences

  5/4/2023

  Sonoma Biotherapeutics, Inc. announced that its Co-founder and Chief Executive Officer, Jeffrey Bluestone, Ph.D., has been elected to the National Academy of Sciences, in recognition of his groundbreaking achievements in immunology and original research.

• AbCellera Reports Q1 2023 Business Results

  5/4/2023

  AbCellera announced financial results for the first quarter of 2023. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated.

• Cocrystal Pharma Presents New Data from its CC-42344 Phase 1 Influenza A Study at the 7th Annual ISIRV Antiviral Group Conference

  5/4/2023

  Cocrystal Pharma, Inc. announces that new data from its CC-42344 Phase 1 influenza A Study was presented by Sam Lee, Ph.D., President and co-CEO, at the 7th Annual International Society for Influenza and Other Respiratory Virus Diseases’ Antiviral Group Conference.

• ImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2023

  5/4/2023

  ImmuCell Corporation, a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, expects to report unaudited financial results for the quarter ended March 31, 2023 after the market closes on Thursday, May 11, 2023.

• ShapeTX Announces Seven Presentations at ASGCT 2023 Showcasing the Potential of Generative AI and RNA in CNS Disorders and Beyond

  5/4/2023

  ShapeTX, the programmable medicine company using AI and RNA to end genetic diseases, today announced seven presentations from across its technology platforms to be featured at the 26th American Society for Gene and Cell Therapy (ASGCT) Annual Meeting taking place May 16-20 in Los Angeles, CA.

• Sound Pharma completes enrollment in pivotal Phase 3 clinical trial of SPI-1005 for the treatment of Meniere's disease involving hearing loss, tinnitus, and dizziness.

  5/3/2023

  Sound Pharmaceuticals is pleased to announce that it has completed enrollment in its first Phase 3 clinical trial involving SPI-1005, a novel anti-inflammatory, for the treatment of Meniere's Disease (STOPMD-3).

• Adaptive Biotechnologies Reports First Quarter 2023 Financial Results

  5/3/2023

  Adaptive Biotechnologies Corporation, a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, reported financial results for the quarter ended March 31, 2023.

• Dalriada brings in former Evotec executive Adam Davenport to lead strategy execution as Chief R&D Officer

  5/3/2023

  Dalriada, a leading Canadian contract research organization specializing in small molecule therapies, announces that it has strengthened its executive leadership team, appointing Adam Davenport, Ph.D. as its Chief Research & Development Officer.